부자의 메탄올 추출물에 의한 신세포암의 증식억제 및 세포사멸 유도

키워드

참고문헌 (49)

1. 김현철, "신장학", pp.419~420 (2006), EPUBLIC
2. 국립암센터 출판부, "암정보", pp.303~ (2004), 국립암센터
3. 박재갑, "종양학", pp.455~458 (2003), 일조각
4. DeKemion JB, "Treatment of advanced renal cell carcinoma-traditional methods and innovative approaches", J Urol, 130, pp.2~7 (1983)
5. Thompson IM, "Improvement in survival of patients with renal cell carcinoma - the role of the serendipitously detected tumor", J Urol, 140, pp.487~490 (1988)
6. Buzaid AC, "Therapeutic options in renal cell carcinoma", Semin Oncol, 2, pp.336~345 (1989)
7. Patel NP, "Renal cell cancer: natural history and results of treatment", J Urol, 119, pp.722~726 (1977)
8. Hermanek P, "Evaluation of the new tumor, node and metastases classification of renal cell carcinoma", J Urol, 144, pp.238~241 (1990)
9. 문구, "암 동서의 결합치료 2", pp.454~458 (1999), 원광대학교출판국
10. 杜鎬京, "東醫腎系學(上)", pp.192~197 (1993), 동양의학연구원
11. 許浚, "東醫寶鑑", pp.1275~1301 (1999), 법인문화사
12. 李元世, "醫鑑重磨百病總括", pp.253~256 (2001), 대성출판사
13. 윤창렬, "難經硏究集成", pp.768~784 (2002)
14. 金質洙, "增損五積丸 腎積方이 腫瘍細胞에 미치는 影響", 원광한의학, 4(1), pp.167~190 (1994)
15. 丁俊宅, "陣苓湯加減方의 抗腫瘍效果에 關한 實驗的 硏究", 대한한방종양학회지, 4(1), pp.37~53 (1998)
16. 田承勳, "竹葉石膏湯加減方이 抗癌化學療法劑의 細胞毒性과 腫瘍細胞의 라이소솜에 미치는 影響", 대한한방종양학회지, 3(1), pp.149~167 (1997)
17. 辛民敎, "臨床本草學", pp.263~264 (1994), 永林社
18. 한방약리학 교재편찬위원회, "한방약리학", pp.430~437 (2005), 도서출판신일상사
19. 김호철, "한방약리학", pp.246~250 (2004), 집문당
20. 통계청, "사망원인 통계(2001-2005)", ~ (2001)
21. 문구, "암 동서의 결합치료 1", pp.55~62 (1999), 원광대학교출판국
22. 楊東喜, "本草備要解析", pp.226~233 (1985), 國興出版社
23. Rosse T, "Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c", Nature, 391, pp.496~499 (1998)
25. Klas C, "Activation interferes with the APO-1 pathway in mature human T cells", Int Immunol, 5, pp.625~630 (1993)
26. Ashkenazi A, "Safety and antitumor activity of recombinant soluble Apo2 ligand", J Clin Invest, 104, pp.155~162 (1999)
27. Ashkenazi A, "Death receptors: signaling and modulation", Science, 281, pp.1305~1308 (1998)
28. Tibbetts MD, "The death effector domain protein family: regulators of cellular homeostasis", Nat Immunol, 4, pp.404~409 (2003)
29. Fulda S, "Exploiting death receptor signaling pathways for tumor therapy", Biochim Biophys Acta, 1705, pp.27~41 (2004)
30. Cheng JQ, "Role of X-linked inhibitor of apoptosis protein in chemoresistance in ovarian cancer: possible involvement of the phosphoinositide-3 kinase", Akt pathway, 2002, pp.5, 131~146
31. Rupprecht HD, "PDGF-induced Egr-1 expression in rat mesangial cells is mediated through upstream serum response elements", Am J Physiol, 265, pp.351~360 (1993)
32. Szabo IL, "NSAIDs inhibit the activation of egr-1 gene in microvascular endothelial cells. A key to inhibition of angiogenesis?", J Physiol Paris, 95, pp.379~383 (2001)
33. Baek SJ, "Resveratrol enhances the expression of non-steroidal anti-inflammatory drug-activated gene (NAG-1) by increasing the expression of p53", Carcinogenesis, 23, pp.425~434 (2002)
34. Chintharlapalli S, "1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl) methanes are peroxisome proliferator-activated receptor gamma agonists but decrease HCT-116 colon cancer cell survival through receptor-independent activation of early growth response-1 and nonsteroidal anti-inflammatory drug-activated gene-1", Mol Pharmacol, 68, pp.1782~1792 (2005)
35. Baek SJ, "Cyclooxygenase inhibitors induce the expression of the tumor suppressor gene Egr-1, which results in the up-regulation of NAG-1, an antitumorigenic protein", Mol Pharmacol, 67, pp.356~364 (2004)
36. Elledge SJ, "Cdk inhibitors: on the threshold of checkpoints and development", Curr Opin Cell Biol, 6, pp.847~852 (1994)
37. Li Y, "Cell cycle expression and p53 regulation of the cyclin-dependent kinase inhibitor p21", Oncogene, 9, pp.2261~2268 (1994)
38. Datto MB, "Functional analysis of thetransforming growth factor β responsive elements in the WAF1", Cip1, J Biol Chem, pp.1995, 270[DOI]
39. Allen RT, "Mechanisms controlling cellular suicide: role of Bcl-2 and caspases", Cell Mol Life Sci, 54, pp.427~445 (1998)
40. Tewari M, "Yama", CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase, 1995, pp.81, 801~809
41. Johnson JP, "Cell adhesion molecules in the development and progression of malignant melanoma", Cancer Metastasis Rev, 18, pp.345~347 (1999)
42. Chang JS, "Overexpression of phospholipase C-gamma1 in rat 3Y1 fibroblast cells leads to malignant transformation", Cancer Res, 57, pp.5465~5468 (1997)
43. Myklebust JH, "Activation of phosphatidylinositol 3-kinase is important for erythropoietin-induced erythropoiesis from CD34(+) hematopoietic progenitor cells", Exp Hematol, 30, pp.990~1000 (2002)
44. Giercksky KE, "COX-2 inhibition and prevention of cancer", Best Pract Res Clin Gastroenterol, 15, pp.821~833 (2001)
45. Vainio H, "Is COX-2 inhibition a panacea for cancer prevention?", Int J Cancer, 94, pp.613~914 (2001)
46. Surh YJ, "Molecular mechanisms underlying chemopreventive activities of anti- inflammatory phytochemicals: down-regulation of COX-2 and iNOS through suppression of NF-κB activation", Mutat Res, 480, pp.243~268 (2001)
47. Poole JC, "Activity, function, and gene regulation of the catalytic subunit of telomerase (hTERT)", Gene, 269, pp.1~12 (2001)
48. Vaziri H, "ATM- dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase", EMBO J, 16, pp.6018~6033 (1997)
49. Cerni C, "Telomeres, telomerase, and myc. An update", Mutat Res, 462, pp.31~47 (2000)

관련 논문AI추천